RITUXIMAB IN RENAL ALLOGRAFT RECIPIENTS WITH EARLY ANTI-HLA ALLOANTIBODIES

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这是一项多中心、单盲、随机、安慰剂对照试验。中心将对1200-1400名受试者进行筛查，并将在3年内随机选择总共134名受试者。这项研究的主要终点是抗CD20单抗治疗去除B细胞在减少慢性体液排斥反应所致的慢性移植肾功能障碍进展方面的有效性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a multi-center, single-blinded, randomized, placebo-controlled trial. Centers will screen 1200-1400 subjects and will randomize a total of 134 subjects over 3 years. The primary endpoint of this study is the effectiveness of B-cell depletion by anti-CD20 mAb therapy in reducing progression of chronic renal allograft dysfunction by chronic humoral rejection.